Volagidemab, a monoclonal antibody (mAb) that antagonizes the glucagon receptor (GCGR), is utilized in researching Type 1 Diabetes (T1D) .

FL118 is a novel survivin inhibitor that inhibits cancer stem cell-like properties.FL118 is a novel camptothecin analog with anticancer activity that inhibits epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway, thereby inhibiting migration and invasion of human breast cancer cells.

[D-Phe12]-Bombesin is a derivative of Bombesin and an antagonist for bombesin receptor with Ki of 4.7 μM. [D-Phe12]-Bombesin inhibits the Bombesin -induced amylase release, with IC50 of 4 μM.